Canaccord lowered the firm’s price target on BioMarin to $112 from $119 and keeps a Hold rating on the shares. The analyst said following the early Jan pre-announcement, much of its 4Q report was uneventful. Canaccord said the pipeline front, timelines around progress and upcoming events are on track.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin price target raised to $127 from $110 at Credit Suisse
- BioMarin sees FY23 EPS under new method of $1.80-$2.05, consensus $1.61
- BioMarin reports Q4 EPS (0c), consensus (7c)
- BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
- Notable companies reporting after market close
